Wall Street coverage of ARWR remains broadly constructive, with most major firms carrying a Buy or Overweight rating and independent aggregators reporting a "Strong Buy" consensus. The individual targets, however, tell a more nuanced story. Averaging the current, attributable targets from firms including Piper Sandler ($126), B. Riley Securities ($123), H.C. Wainwright ($120), UBS ($109), Morgan Stanley ($106), Stifel ($96), Bank of America ($93), Chardan Capital ($90), RBC Capital ($87), and Goldman Sachs ($85, Hold) produces a mean near $105, which we use as the central target. Bernstein's more cautious $46 Hold target sits well below that cluster, and the full range from roughly $46 to $126 is unusually wide. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent revisions reflect a split in confidence. Morgan Stanley lowered its target to $106 from $120, and Stifel trimmed to $96 from $104, while UBS initiated coverage with a Buy and a $109 target and Piper Sandler and B. Riley maintained targets above $120. Bullish analysts emphasize the commercial de-risking of REDEMPLO and the scale of the sHTG opportunity; cautious analysts point to thin current revenue, heavy spending, and execution risk in commercial build-out.
At approximately $47.78, ARWR sits near the middle of its 52-week range of roughly $37 to $95, with a market capitalization around $6.8 billion. Reaching $105 would require a gain of about 120% — a very large move that would essentially require the market to re-rate the stock from a pre-commercial RNAi developer to a credible, revenue-generating cardiometabolic franchise.
The path runs through REDEMPLO. The drug is approved for FCS in multiple markets, and the company has filed a supplemental new drug application (sNDA) for sHTG under the FDA's STAR pilot program, targeting a potential U.S. launch in the second quarter of 2027. Late-stage SHASTA-3 and SHASTA-4 data showed median triglyceride reductions of 79% and 81% and a 78% reduction in acute pancreatitis events. Yet fiscal 2026 results underscore the gap between promise and profit: revenue of about $450.8 million was down 46% year over year, and the company posted a net loss of roughly $724 million, or $5.11 per share, missing consensus.
ARWR has been range-bound after pulling back from its 52-week high near $95, with durable support in the mid-to-high $30s around its 52-week low of roughly $37. Resistance is layered: the psychological $50 level sits just overhead, followed by prior congestion near $60 and the larger supply zone approaching $95. Reaching $105 would require a sustained breakout above that prior high, implying a structural trend change rather than a routine recovery. The stock's decline after its fiscal-year earnings miss suggests technical momentum remains weak in the near term. From what I see, the AI Trend Prediction Engine helps highlight these key levels more clearly.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. Key items to watch include the FDA's PDUFA date for the sHTG supplement (expected in the weeks ahead), payer-coverage and prescription-conversion metrics each quarter, the pace of REDEMPLO revenue recognition, and any updates on the ARO-DIMER-PA and ARO-MAPT pipeline programs. Because the company is changing its fiscal year end from September 30 to December 31, investors should also note the timing of upcoming transition-period filings and earnings reports, as well as further analyst target revisions in either direction.
In my view, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to complement traditional research on names like ARWR. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions, technical behavior, and AI-driven analysis. For a volatile stock, these signals can help identify momentum shifts and trend changes more efficiently than manual checks alone. Traders often use them to spot new opportunities, track positions, and stay ahead of developments. I find this approach particularly useful when reviewing clinical-stage biotechs where sentiment can shift quickly.
The $105 central target for Arrowhead Pharmaceuticals represents the average of a wide range of analyst views, and it implies a roughly 120% advance from the current price near $47.78 — a very large move. The bull case rests on REDEMPLO's launch into severe hypertriglyceridemia, compelling late-stage efficacy data, and an expedited regulatory path. The bear case centers on minimal current revenue, deep losses, an uncertain conversion funnel, a diabetes-related safety signal, and fierce competition. The unusually wide $46-to-$126 analyst range reflects genuine uncertainty about how quickly clinical promise becomes commercial reality. Investors should watch the sHTG regulatory decision, payer coverage, and prescription conversion most closely, while treating the $105 figure as an analytical benchmark rather than a forecast. I'm watching this closely as the regulatory timeline unfolds.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ARWR advanced for three days, in 222 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARWR as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ARWR turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 33 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for ARWR moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ARWR entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.647) is normal, around the industry mean (3.592). P/E Ratio (-25.509) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of novel drugs to treat intractable diseases
Industry Biotechnology